No Data
Wells Fargo Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $50
Wells Fargo analyst Larry Biegelsen maintains $Tandem Diabetes Care(TNDM.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 58.
Is weight loss medicine or stock market bomb? Eli Lilly and Co's new drug tirzepatide caused a sharp drop in sleep device stocks.
The recent clinical trial results of the new weight loss drug tirzepatide have not only caused a sensation in the medical community, but also stirred up waves in the stock market.
Tandem Diabetes, DexCom See Weakness Following ADA Conference
Lake Street Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $75
Lake Street analyst Brooks O'Neil maintains $Tandem Diabetes Care(TNDM.US)$ with a buy rating, and maintains the target price at $75.According to TipRanks data, the analyst has a success rate of 43.9%
TD Cowen Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $45
TD Cowen analyst Josh Jennings maintains $Tandem Diabetes Care(TNDM.US)$ with a buy rating, and maintains the target price at $45.According to TipRanks data, the analyst has a success rate of 50.8% an
Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions
PDF Version SAN DIEGO--(BUSINESS WIRE)--Jun. 22, 2024-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today presented new real-world insight